Hi Kabunushi, my understanding and this also was the case way back when cell based companies did not have CDMO’s generally available, was that they have to be scaled and operational effectively to get a commercial license and you need the commercial license to get the marketing license. So nothing comes cheap, unfortunately. But by having the regional authority funding to develop Sawston, and the obligation to provide local manufacturing initially with excess capacity, you get potentially some subsidization and scaling early without only needing DCVax-L manufacturing. So the model NWBO/LP created here in my opinion was quite ingenious.